Intellipharmaceutics International Inc. (IPCI)

0.617721 +0.00796 (+1.305%)

IEX Real-Time Price

October 19, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 0.609763

Price Open 0.585

Volume: 356,192

Avg Volume: 414,672

Market Cap: 26.43M

P/E Ratio -0.19

52 Wk Range 0.57-10.5



IPCI Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-09-28
4.35M
284,872
5.33
6.54%

2018-09-14
4.35M
277,913
8.10
6.38%

2018-08-31
43.54M
2.28M
12.48
5.24%

2018-08-15
43.54M
2.08M
20.54
4.79%




IPCI Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-07-16
Q2 2018
N/A
-0.07 (1)
-0.07
0.00

2018-05-01
Q1 2018
N/A
-0.05 (1)
0.00
0.00

2018-04-24
Q1 2018
N/A
-0.05 (1)
0.00
0.00

2018-04-17
Q1 2018
N/A
-0.05 (1)
0.00
0.00

News

IntelliPharmaCeutics misses by $0.51, misses on revenue (2018-10-16 15:47 SeekingAlpha)

IntelliPharmaCeutics (NASDAQ: IPCI ): Q3 GAAP EPS of -$0.91 misses by $0.51. Revenue of $0.41M (-65.5% Y/Y) misses by $1.48M . Press Release More news on: IntelliPharmaCeutics International Inc, Earnings news and commentary, Healthcare stocks news, ,

 


Statistics

Shares Outstanding: 4.35M

Top 15 Institution Percent: 266.30

Price To Sales: 8.20

Price To Book: 62.79

Revenue: 2.27M

Gross Profit: 1.77M

Cash: 2.63M

Debt: N/A

Return On Assets: -207.83

Return On Equity: 436.35

Profit Margin: N/A

Price History

Beta: 2.03

50-day Moving Avg: 2.40

200-day Moving Avg: 4.70

YTD Change: -92.66

5-day Change: -2.87

1-month Change: -75.39

3-month Change: -84.86

6-month Change: -88.54

1-year Change: -93.70

Revenue Per Share: 1.00

Revenue Per Employee: 36574.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Intellipharmaceutics International Inc.

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The Company is engaged in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs.